生命科学行业的数字化颠覆图景_16页_1mb

报告摘要

Summary of "Charting Digital Disruption in the Life Sciences Sector"

Core Content

This whitepaper provides an analysis of the adoption and impact of digital technologies in the life sciences sector, based on a 2024 survey of 101 professionals from pharmaceutical, biopharmaceutical, and biotechnology companies. It builds on a 2019 survey and explores how the industry has evolved in its approach to digital transformation, highlighting both progress and ongoing challenges.

Main Views and Key Information

Digital Transformation in Drug Development

Rising Adoption of AI and Big Data: 49% of respondents in 2024 reported that their organisation was actively using AI and big data analytics in development programs, up from 39% in 2019. The number of organisations piloting these technologies also increased from 29% to 35%.
Systemic Integration Challenges: Despite increased usage, only 13% of organisations have a comprehensive program for integrating AI and big data into development projects, showing that systemic adoption is still limited.
Shift in Perception: The proportion of respondents who believed digital technologies would have no effect on operations dropped from 29% in 2019 to 11% in 2024, indicating growing recognition of their value.

Value Propositions of Digital Tools

High Impact Areas: Respondents identified predictive tools, biomarker discovery, and safety and efficacy signal detection as the most promising areas for digital technologies in R&D, with 46%, 44%, and 43% respectively indicating "great value."
Other High Potential Areas: These include preclinical research, refining dosing and protocols based on real-world evidence, patient recruitment, rapid diagnosis, and improved communication with customers.
Consistent Ratings: The perceived value of digital tools across different R&D areas has remained relatively stable since 2019, suggesting a mature understanding of their potential.

Drivers for Adoption

Improving ROI: 82% of respondents believe digital tools will improve return on R&D investments.
Enhancing Product Safety and Efficacy: 76% of respondents believe digital tools will enhance product safety and efficacy.
Competing in Targeted Markets: 76% of respondents believe digital technologies will help organisations compete in targeted medicine markets, which has moved up in importance over the past five years.

Barriers to Adoption

Decreasing Perceived Barriers: On average, the significance of barriers to digital adoption has decreased since 2019, with 58% of respondents now identifying a lack of regulatory support as the most significant current barrier.
Regulatory Constraints: The European Union's AI Act is cited as a recent event that may have increased the perception of regulatory challenges.

Investment Trends

Increased Spending: 88% of respondents expect their organisation to increase investment in digital-enabled technologies over the next one to two years, with an estimated 34% average increase and 27% of organisations planning to increase spending by over 41%.
Partnership Strategies: While internal development remains a key strategy, there is a growing preference for partnerships with technology consultants and companies over CROs, reflecting a shift in how organisations are approaching digital maturity.

Strategies for Future Success

Strategic Investment: Organisations must focus on areas where digital tools can deliver measurable value, such as predictive modelling, biomarker discovery, and patient recruitment.
Leverage Partnerships: Strategic collaborations with technology vendors, CROs, and consultants can accelerate digital integration and improve competitive positioning.
Regulatory Engagement: Proactive engagement with regulatory bodies is essential to overcome barriers and ensure the development of supportive frameworks.
Organisational Readiness: Building a culture of digital literacy and innovation through training, cross-functional collaboration, and leadership alignment is crucial for a successful digital transformation.

Conclusion

The life sciences sector is undergoing significant digital disruption, with a growing recognition of the value of AI, machine learning, and big data analytics in drug development. While adoption is increasing, systemic integration remains a challenge. The report serves as a roadmap for biopharma leaders to make informed decisions that drive innovation, enhance R&D productivity, and ultimately improve patient outcomes. The future of drug development is being redefined, and organisations that act decisively will lead the way.